Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination/prednisolone therapy

Nephrol Dial Transplant. 2011 Jan;26(1):163-9. doi: 10.1093/ndt/gfq387. Epub 2010 Jul 2.

Abstract

Background: The prognosis of children with severe IgA nephropathy showing diffuse mesangial proliferation is poor. However, the prognosis can be improved by combination therapy (prednisolone + azathioprine or mizoribine + warfarin + dipyridamole) or prednisolone alone over a 2-year period, and disappearance of glomerular IgA deposits is often observed. Details of the incidence and clinicopathological significance of glomerular IgA disappearance remain unclear.

Methods: To investigate this phenomenon, we retrospectively screened and analysed 124 consecutive children (age ≤ 18 years at first biopsy) with newly diagnosed severe IgA nephropathy showing diffuse mesangial proliferation, who received combination therapy or prednisolone alone for 2 years and underwent repeat biopsies.

Results: Among these patients, 90 received combination therapy, and 34 received prednisolone alone. After 2 years of treatment, 27 of the patients (21.8%) showed disappearance of glomerular IgA. Logistic analysis showed that IgA disappearance was associated with less severe urinary protein excretion at the end of treatment. Kaplan-Meier analysis of the long-term course revealed a significant difference in proteinuria-free survival after the 2-year treatment period between the patients with IgA disappearance and those without (P = 0.008; log-rank test). The Cox proportional hazards model showed that disappearance of glomerular IgA after the treatment was a factor significantly associated with proteinuria-free survival in both univariate and multivariate analyses.

Conclusions: The present results suggest that disappearance of IgA after 2 years of treatment indicates milder disease severity, even in patients with diffuse mesangial proliferation, and is a prognostic factor related to proteinuria-free survival.

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use*
  • Anticoagulants / therapeutic use
  • Azathioprine / therapeutic use
  • Child
  • Dipyridamole / therapeutic use
  • Drug Therapy, Combination
  • Female
  • Glomerular Mesangium / drug effects*
  • Glomerular Mesangium / immunology
  • Glomerulonephritis, IGA / drug therapy*
  • Glomerulonephritis, IGA / immunology
  • Glomerulonephritis, IGA / pathology
  • Humans
  • Immunoglobulin A / immunology*
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Glomerulus / drug effects
  • Kidney Glomerulus / metabolism
  • Kidney Glomerulus / pathology
  • Male
  • Prednisolone / therapeutic use*
  • Retrospective Studies
  • Ribonucleosides / therapeutic use
  • Survival Rate
  • Treatment Outcome
  • Vasodilator Agents / therapeutic use
  • Warfarin / therapeutic use

Substances

  • Anti-Inflammatory Agents
  • Anticoagulants
  • Immunoglobulin A
  • Immunosuppressive Agents
  • Ribonucleosides
  • Vasodilator Agents
  • mizoribine
  • Warfarin
  • Dipyridamole
  • Prednisolone
  • Azathioprine